PE20120780A1 - Nicotinamida sustituida como moduladores kcnq2/3 - Google Patents

Nicotinamida sustituida como moduladores kcnq2/3

Info

Publication number
PE20120780A1
PE20120780A1 PE2011001566A PE2011001566A PE20120780A1 PE 20120780 A1 PE20120780 A1 PE 20120780A1 PE 2011001566 A PE2011001566 A PE 2011001566A PE 2011001566 A PE2011001566 A PE 2011001566A PE 20120780 A1 PE20120780 A1 PE 20120780A1
Authority
PE
Peru
Prior art keywords
methyl
pyridin
kcnq2
acid amide
nicotinamide
Prior art date
Application number
PE2011001566A
Other languages
English (en)
Inventor
Sven Kuhnert
Beatrix Merla
Gregor Bahrenberg
Wolfgang Schroder
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40933299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120780(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20120780A1 publication Critical patent/PE20120780A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

SE REFIERE A COMPUESTOS DE NICOTINAMIDA SUSTITUIDA DE FORMULA (1) DONDE R1 ES ALQUILO(C1-C10), HETEROALQUILO(C2-C10), CICLOALQUILO(C3-C10), ARILO, ENTRE OTROS; R2, R3 Y R4 SON CADA UNO H, F, NO2, CF3, CN, METILO, ENTRE OTROS; A1 ES CR10R11 O S; A2 ES C(=O), O, S, S(=O)2, ENTRE OTROS; R5, R6, R7, R8, R10 Y R11 SON CADA UNO H, CF3, OH, OCF3, SH, ALQUILO(C1-C10), ENTRE OTROS; R9 ES CICLOALQUILO(C3-C10), HETEROCICLILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: AMIDA DE ACIDO 2-(3-FENILO-PROPILSULFANIL)-N-(TIOFEN-2-IL-METIL)-PIRIDIN-3-CARBOXILICO; AMIDA DE ACIDO 2-(3-CICLOHEXIL-PROPILSULFANIL)-N-(TIOFEN-2-IL-METIL)-PIRIDIN-3-CARBOXILICO; AMIDA DE ACIDO 2-[(3-OXO-3-FENIL-PROPIL)SULFANIL]-N-(TIOFEN-2-IL-METIL)-PIRIDIN-3-CARBOXILICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL CANAL DE K+ KCNQ2/3 SIENDO UTILES EN EL TRATAMIENTO DEL DOLOR, EPILEPSIA, INCONTINENCIA URINARIA, MIGRANA
PE2011001566A 2009-03-12 2010-03-11 Nicotinamida sustituida como moduladores kcnq2/3 PE20120780A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09003598 2009-03-12

Publications (1)

Publication Number Publication Date
PE20120780A1 true PE20120780A1 (es) 2012-06-20

Family

ID=40933299

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001566A PE20120780A1 (es) 2009-03-12 2010-03-11 Nicotinamida sustituida como moduladores kcnq2/3

Country Status (28)

Country Link
US (2) US8178684B2 (es)
EP (1) EP2406226B1 (es)
JP (1) JP5670359B2 (es)
KR (1) KR20110132592A (es)
CN (1) CN102369188B (es)
AR (1) AR075540A1 (es)
AU (1) AU2010223511B2 (es)
BR (1) BRPI1008948A2 (es)
CA (1) CA2754998C (es)
CO (1) CO6410303A2 (es)
CY (1) CY1116787T1 (es)
DK (1) DK2406226T3 (es)
EC (1) ECSP11011347A (es)
ES (1) ES2556772T3 (es)
HK (1) HK1166061A1 (es)
HR (1) HRP20151260T1 (es)
HU (1) HUE026170T2 (es)
IL (1) IL214946A (es)
MX (1) MX2011009127A (es)
NZ (1) NZ595628A (es)
PE (1) PE20120780A1 (es)
PL (1) PL2406226T3 (es)
PT (1) PT2406226E (es)
RU (1) RU2529904C2 (es)
SI (1) SI2406226T1 (es)
TW (1) TWI475020B (es)
WO (1) WO2010102809A1 (es)
ZA (1) ZA201107442B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
WO2010102778A2 (de) * 2009-03-10 2010-09-16 Grünenthal GmbH Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
JP5887345B2 (ja) 2010-08-27 2016-03-16 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換２−アミノ−キノリン−３−カルボキサミド
ES2537628T3 (es) 2010-08-27 2015-06-10 Grünenthal GmbH 2-Oxiquinolin-3-carboxamidas sustituidas como moduladores de KCNQ2/3
CN103189357B (zh) 2010-08-27 2015-11-25 格吕伦塔尔有限公司 作为kcnq2/3调节剂的取代的2-氧代-和2-硫代-二氢喹啉-3-甲酰胺
US8618129B2 (en) 2010-09-01 2013-12-31 Gruenenthal Gmbh Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators
AU2015201122B2 (en) * 2010-10-20 2016-02-25 Grunenthal Gmbh Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
KR101820645B1 (ko) * 2010-10-20 2018-01-22 그뤼넨탈 게엠베하 Ｋｃｎｑ２／３ 조절제로서의 치환된 ６­아미노­니코틴아미드
US9168259B2 (en) 2010-10-20 2015-10-27 Grünenthal GmbH Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
FR2968661B1 (fr) * 2010-12-14 2016-01-01 Oreal Procede de depigmentation des matieres keratiniques a l'aide de composes thiopyridinones
EP2844645A1 (en) 2012-04-18 2015-03-11 Grünenthal GmbH Substituted 4-aminobenzamides as kcnq2/3 modulators
JP6033403B2 (ja) * 2012-04-18 2016-11-30 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としてのｏｈ含有基を有する置換６−アミノ−ニコチンアミド類
WO2014056620A1 (en) * 2012-10-11 2014-04-17 Grünenthal GmbH Treatment and/or prophylaxis of tspo mediated diseases and/or disorders
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
WO2014082737A1 (en) 2012-11-28 2014-06-05 Grunenthal Gmbh Specific carboxamides as kcnq2/3 modulators
CN104513171B (zh) * 2013-09-30 2017-09-01 中国科学院过程工程研究所 一种玛咖酰胺的合成方法及其用途
CA2965467A1 (en) 2014-10-24 2016-04-28 Ono Pharmaceutical Co., Ltd. Kcnq2-5 channel activator
JP7120549B2 (ja) * 2016-12-15 2022-08-17 小野薬品工業株式会社 Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ
DE102018212006B3 (de) 2018-07-18 2019-10-31 Universität Greifswald Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen
CN111840267A (zh) * 2020-08-05 2020-10-30 牡丹江医学院 一种治疗小儿口腔黏膜疾病的药物及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532939A1 (fr) 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (fr) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Derives de l'arylthioacetamide
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
JP2003506387A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド カリウムチャンネルオープナーとしてのベンズアニリド
WO2001010381A2 (en) * 1999-08-04 2001-02-15 Icagen, Inc. Methods for treating or preventing pain and anxiety
JP5049447B2 (ja) * 2000-08-14 2012-10-17 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
WO2002072088A2 (en) 2001-02-20 2002-09-19 Bristol-Myers Squibb Company Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
CZ20032233A3 (cs) * 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
US7087758B2 (en) 2001-04-06 2006-08-08 Smithkline Beecham Corporation Quinoline inhibitors of hyaki and hyak3 kinases
EP1542966A1 (en) 2002-09-17 2005-06-22 Pharmacia Corporation Aromatic liver x-receptor modulators
DE60335028D1 (de) 2002-12-23 2010-12-30 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
US7598412B2 (en) * 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EA200601830A1 (ru) * 2004-05-04 2007-04-27 Пфайзер Инк. Ортозамещённые арильные или гетероарильные амидные соединения
CA2585490A1 (en) 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
EP2298766B1 (en) 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmaceutical formulations comrpising a substituted pyridine derivative
ATE432259T1 (de) 2005-07-20 2009-06-15 Lilly Co Eli Pyridinderivate als dipeptedyl-peptidase-hemmer
US7670416B2 (en) * 2005-08-04 2010-03-02 I-Tech Ab Use of a combination of substances to prevent biofouling organisms
CN101277939A (zh) 2005-09-09 2008-10-01 布里斯托尔-迈尔斯斯奎布公司 无环ikur抑制剂
JP2009515934A (ja) 2005-11-18 2009-04-16 ノイロサーチ アクティーゼルスカブ 新規なキナゾリン誘導体及びこれらの医学的使用
WO2008011110A2 (en) 2006-07-20 2008-01-24 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
DE602007004638D1 (de) 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
US20080039542A1 (en) * 2006-08-11 2008-02-14 General Electric Company Composition and associated method
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
WO2009019149A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
DE102007044277A1 (de) * 2007-09-17 2009-03-19 Grünenthal GmbH Substituierte Nicotinamid-Verbindungen und deren Verwendung in Arzneimitteln
CA2702469A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
US8367700B2 (en) 2008-12-17 2013-02-05 Gruenenthal Gmbh Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
WO2010102778A2 (de) 2009-03-10 2010-09-16 Grünenthal GmbH Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TWI461197B (zh) 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
JP5887345B2 (ja) 2010-08-27 2016-03-16 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換２−アミノ−キノリン−３−カルボキサミド
BR112013004721A2 (pt) 2010-08-27 2016-05-17 Gruenenthal Gmbh "quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3"

Also Published As

Publication number Publication date
HK1166061A1 (en) 2012-10-19
AR075540A1 (es) 2011-04-20
JP5670359B2 (ja) 2015-02-18
ECSP11011347A (es) 2011-10-31
US20100234429A1 (en) 2010-09-16
PL2406226T3 (pl) 2016-02-29
IL214946A (en) 2016-02-29
JP2012520247A (ja) 2012-09-06
IL214946A0 (en) 2011-11-30
CO6410303A2 (es) 2012-03-30
US8586755B2 (en) 2013-11-19
MX2011009127A (es) 2011-09-26
US20120184550A1 (en) 2012-07-19
KR20110132592A (ko) 2011-12-08
CN102369188A (zh) 2012-03-07
TW201035087A (en) 2010-10-01
SI2406226T1 (sl) 2015-12-31
PT2406226E (pt) 2016-01-12
RU2529904C2 (ru) 2014-10-10
CA2754998A1 (en) 2010-09-16
AU2010223511A1 (en) 2011-11-03
CA2754998C (en) 2013-08-27
US8178684B2 (en) 2012-05-15
AU2010223511B2 (en) 2015-06-11
CN102369188B (zh) 2016-03-02
BRPI1008948A2 (pt) 2016-03-15
HUE026170T2 (en) 2016-05-30
NZ595628A (en) 2012-10-26
HRP20151260T1 (hr) 2016-01-01
CY1116787T1 (el) 2017-03-15
ES2556772T3 (es) 2016-01-20
ZA201107442B (en) 2012-07-25
WO2010102809A1 (de) 2010-09-16
TWI475020B (zh) 2015-03-01
EP2406226A1 (de) 2012-01-18
DK2406226T3 (en) 2015-10-05
EP2406226B1 (de) 2015-09-16
RU2011141186A (ru) 2013-04-20

Similar Documents

Publication Publication Date Title
PE20120780A1 (es) Nicotinamida sustituida como moduladores kcnq2/3
PE20120790A1 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3
PE20142452A1 (es) AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2
PE20120667A1 (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
PE20140199A1 (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3
PE20131350A1 (es) Compuestos sustituidos de benzamida
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
PE20121058A1 (es) Compuestos que modulan el receptor de androgenos
AR094277A1 (es) Derivados de fumarato sustituidos con deuterio
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20091557A1 (es) Derivados de piridazina y su uso como agentes terapeuticos
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
MX2013012798A (es) Compuestos heterociclicos fusionados como moduladores del canal de sodio.
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
PE20091590A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos
PE20121640A1 (es) Derivados de pirazina como inhibidores de bace
PE20121522A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PE20071227A1 (es) Compuestos derivados de indazol como moduladores del receptor de glucocorticoides
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20150403A1 (es) Pirrol carboxamidas fluorometilo sustituidas
MX2011007663A (es) Compuestos de sulfona heterociclica, saturada y sustituida en n, con actividad agonistica del receptor de cb2.
PE20150709A1 (es) Benzamidas
PE20150021A1 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed